Loading
ZRSR2 (U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Skin cancer and 2 more.
Pre-mRNA-binding protein required for splicing of both U2- and U12-type introns. Selectively interacts with the 3'-splice site of U2- and U12-type pre-mRNAs and promotes different steps in U2 and U12 intron splicing. Recruited to U12 pre-mRNAs in an ATP-dependent manner and is required for assembly of the pre-spliceosome, a precursor to other spliceosomal complexes.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.42, genetic association 0.00, somatic mutation 0.82). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Acute Myeloid Leukaemia.
In plain words · ZRSR2 (U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Skin cancer and 2 more.
ZRSR2 (U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Skin cancer and 2 more.
Pre-mRNA-binding protein required for splicing of both U2- and U12-type introns. Selectively interacts with the 3'-splice site of U2- and U12-type pre-mRNAs and promotes different steps in U2 and U12 intron splicing.
No product in this corpus aims at ZRSR2 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it a tumour suppressor (IntOGen finds it knocked out more often than chance); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA ZRSR2: RNA low tissue specificity; no normal tissue stained high. Distribution: 4 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Myeloid neoplasms, Leukaemia, Skin cancer (all types), Lymphoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q15696; CIViC gene ZRSR2; IntOGen ZRSR2; Human Protein Atlas ZRSR2 tissue; Open Targets ENSG00000169249 associations
First described 1995. Earliest sequence paper UniProt cites for the protein: Kitagawa et al, Genomics, 1995, "Isolation and mapping of human homologues of an imprinted mouse gene U2af1-rs1". Source.
Sources: HGNC HGNC:23019 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q15696 (protein name, function text, keywords and locations (REST API)); CIViC gene ZRSR2 (1 evidence items, 0 assertions, 1 variants; diseases: Acute Myeloid Leukaemia (GraphQL API, CC0)); Open Targets ENSG00000169249 (association with cancer (MONDO_0004992) 0.63; per-cancer scores at or above 0.5: non-Hodgkin lymphoma 0.51, skin cancer 0.52, myeloproliferative neoplasm 0.59, leukaemia 0.57 (GraphQL API, CC0)); IntOGen ZRSR2 (driver in 1 cohort (Act 0, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Pre-mRNA-binding protein required for splicing of both U2- and U12-type introns. Selectively interacts with the 3'-splice site of U2- and U12-type pre-mRNAs and promotes different steps in U2 and U12 intron splicing. Recruited to U12 pre-mRNAs in an ATP-dependent manner and is required for assembly of the pre-spliceosome, a precursor to other spliceosomal complexes. For U2-type introns, it is selectively and specifically required for the second step of splicing. Location: Nucleus (UniProt). Locus Xp22.2 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high.
No cancer sample stained medium or high.
HPA ZRSR2 tissue · HPA ZRSR2 pathology · HPA protein class: Essential proteins
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"ZRSR2" OR ABSTRACT:"ZRSR2" OR TITLE:"zinc finger CCCH-type, RNA binding motif and serine/arginine rich 2" OR ABSTRACT:"zinc finger CCCH-type, RNA binding motif and serine/arginine rich 2" OR TITLE:"U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 2" OR ABSTRACT:"U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 2" OR TITLE:"U2AF1-RS2" OR ABSTRACT:"U2AF1-RS2" OR TITLE:"ZC3H22" OR ABSTRACT:"ZC3H22" OR TITLE:"U2AF1L2" OR ABSTRACT:"U2AF1L2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ZRSR2, not a curated reading list.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), CIViC.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, IntOGen.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), CIViC, Acute myeloid leukaemia.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), CIViC.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), CIViC.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), Acute myeloid leukaemia.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), CIViC.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), Acute myeloid leukaemia.